Logo.png
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
December 13, 2024 16:05 ET | Palisade Bio, Inc.
Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
barinthuslogo.jpg
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
November 25, 2024 16:01 ET | Barinthus Biotherapeutics
OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), today announced the promotion of Geoffrey Lynn, M.D.,...
cmi_logo.png
[Latest] Global Injectable Drug Delivery Devices Market Size/Share Worth USD 40,956.3 Million by 2033 at a 10.21% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
November 25, 2024 11:30 ET | Custom Market Insights
Austin, TX, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Injectable Drug Delivery Devices Market Size, Trends and Insights By Device Type...
Caribou_logo.png
Caribou Biosciences to Participate in Upcoming Investor Conferences
November 20, 2024 16:00 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
November 19, 2024 16:30 ET | Conduit Pharmaceuticals
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
barinthuslogo.jpg
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
November 06, 2024 08:00 ET | Barinthus Biotherapeutics
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
barinthuslogo.jpg
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
October 31, 2024 08:00 ET | Barinthus Biotherapeutics
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
Caribou_logo.png
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
September 25, 2024 09:00 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract...
barinthuslogo.jpg
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
September 24, 2024 08:00 ET | Barinthus Biotherapeutics
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
EpimAb_Logo_For Notified.png
EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody
September 03, 2024 21:00 ET | Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI and SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, Inc. (“EpimAb” or “EpimAb Biotherapeutics”) a clinical stage biopharmaceutical company specializing in the...